Publications
Included here is a list of publications from OCG programs. All published data are available to the research community through the program-specific data matrices.
* denotes publications from the CTD2 initiative that are results of intra-Network collaborations
Authors find a previously unknown mutant fusion of RET tyrosine kinase in a case of medullary thyroid carcinoma.
Researchers identify FRS2 as an oncogene in a subset of high-grade serous ovarian cancers.
Combination therapy of ruxolitinib and dasatinib extends survival and prevents relapse of a mouse model of Ph+ ALL.
Researchers discuss parallel genetic evolution of separate metastatic sites with different PTEN genomic alterations leads to a convergent PTEN-null phenotype resistant to PI(3)Kα inhibition
The study reported that the most common single-nucleotide substitution/deletion mutations in favorable histology Wilms tumors occur within SIX1/2, and microRNA processing genes DGCR8 and DROSHA. SIX and miRNAPG mutations were reported to be associated with RAS activation.
Investigators identify the role of GATA2 in chemotherapy resistance in prostate cancer.
Researchers generate a systematic and quantitative chemical-genetic interaction map that measures the influence of 51 aberrant cancer genes on 90 drug responses.
Researchers describe quantitative trait loci associated with differential splicing in neuroblastoma to identify genes with previously unknown functions within the splicing pathway and to define de novo intronic splicing motifs that influence splicing from hundreds of bases away.